Before the Bell: Genentech, ImClone Rise  NEW YORK (Reuters) - Shares of Genentech Inc. &lt;A HREF="http://www.investor.reuters.com/FullQuote.aspx?ticker=DNA.N target=/stocks/quickinfo/fullquote"&gt;DNA.N&lt;/A&gt;, OSI  Pharmaceuticals Inc. &lt;A HREF="http://www.investor.reuters.com/FullQuote.aspx?ticker=OSIP.O target=/stocks/quickinfo/fullquote"&gt;OSIP.O&lt;/A&gt; and ImClone Systems Inc. &lt;A HREF="http://www.investor.reuters.com/FullQuote.aspx?ticker=IMCL.O target=/stocks/quickinfo/fullquote"&gt;IMCL.O&lt;/A&gt;  surged before the bell on Friday after rival AstraZeneca Plc  &lt;A HREF="http://www.investor.reuters.com/FullQuote.aspx?ticker=AZN.L target=/stocks/quickinfo/fullquote"&gt;AZN.L&lt;/A&gt; said its lung cancer drug Iressa failed to show  survival benefits in a major clinical study.